Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Picato for Molluscum Contagiosum in Immunocompromised Patients
NCT03336372Phase 1Withdrawn
- Start
- Dec 2017
- Primary completion
- Sep 2018
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ingenol mebutate in molluscum contagiosum (MC). Primary endpoint: Complete clearance at Week 4. Planned start Dec 2017; status: withdrawn.
02
Drugs
ingenol mebutate
03
Conditions
molluscum contagiosum (MC)
Beyond the preview
Go deeper on NCT03336372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03336372.